CompletedInterventionalPhase 4Updated Jan 10, 2020
Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy | NCT02072408 | Trialant
CompletedInterventionalPhase 4Updated Sep 5, 2018
Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy
ClinicalTrials.gov ID
NCT02072408
Lead Sponsor
Samsung Medical CenterOTHER
Overall Status
Completed
Study Type
Interventional
Phase
Phase 4
Enrollment
46Actual
Last Update Posted
Sep 5, 2018Actual
Start Date
Feb 2014
Primary Completion Date
Nov 2, 2017Actual
Completion Date
Nov 2, 2017Actual
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of aflibercept for treatment of polypoidal choroidal vasculopathy without active polyp.
Polypoidal Choroidal Vasculopathy Without Active Polyp
aflibercept
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
polypoidal choroidal vasculopathy without active polyp
decreased visual acuity by subretinal fluid and hemorrhage involving foveal center
Exclusion Criteria:
polypoidal choroidal vasculopathy with active polyp
previous photodynamic therapy more than three times
anti-VEGF injection within one month
photodynamic therapy or intraocular steroid treatment within three months